Can Fite Biofarma (Can Fite Biofarma) Other Long-Term Liabilities

: $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

Can Fite Biofarma's other long-term liabilities for the quarter that ended in Dec. 2023 was $0.00 Mil.

Can Fite Biofarma's quarterly other long-term liabilities stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil) but then declined from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Can Fite Biofarma's annual other long-term liabilities stayed the same from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.00 Mil) but then declined from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Can Fite Biofarma Other Long-Term Liabilities Historical Data

The historical data trend for Can Fite Biofarma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Can Fite Biofarma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities																-	-	-	-	-

Can Fite Biofarma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Can Fite Biofarma Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (Can Fite Biofarma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).